Center-Authored Papers

Filters: Author is Mack, Philip C  [Clear All Filters]
2017
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS et al..  2017.  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.. Clinical genitourinary cancer. Abstract
2015
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.  2015.  Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.. Clinical lung cancer. Abstract
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR.  2015.  Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(1):110-5. Abstract
Ou S-HI, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR.  2015.  SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(2):387-91. Abstract
Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR.  2015.  SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD et al..  2015.  Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7):1514-24. Abstract
2014
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA et al..  2014.  Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR.  2014.  Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC.  2014.  Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications.. Clinical lung cancer. 15(1) Abstract
Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ et al..  2014.  Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.. Journal of the National Cancer Institute. Abstract
Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ et al..  2014.  A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).. Cancer. Abstract
2013
Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV et al..  2013.  Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk PJ et al..  2013.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.. The lancet oncology. 14(9):893-900. Abstract
2012
Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW.  2012.  Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity.. Clinical lung cancer.
2010
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
2009
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK et al..  2009.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3540-6. Abstract
2008
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley J et al..  2008.  Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(9):1026-31. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract